Investigating the immune response to HPV vaccines

HPV Serology

NIH-funded research Leidos Biomedical Research, INC. · NIH-11219752

This study is looking at how well different HPV vaccines work by checking the immune response they create, especially against high-risk types like HPV 16 and 18, to see if just one dose could be as effective as the usual three doses, which could help improve vaccination methods and better protect against cervical cancer.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionLeidos Biomedical Research, INC. NIH-funded
Lab location1 site (Frederick, United States)
Project IDNIH-11219752 on NIH RePORTER

What this research studies

This research focuses on understanding the immune response generated by different HPV vaccines, specifically looking at the antibodies produced against high-risk HPV types like HPV 16 and HPV 18. The study aims to establish standardized serological measures to evaluate vaccine efficacy, which is currently complicated by the use of pooled human serum as a reference. By developing a new calibration method for measuring vaccine-induced immunity, the research hopes to clarify whether a single dose of the vaccine could be as effective as the standard three-dose regimen. This could lead to improved vaccination strategies and better protection against cervical cancer.

Who could benefit from this research

Good fit: Ideal candidates for this research include individuals who are eligible for HPV vaccination or those who have received the vaccine and are interested in understanding their immune response.

Not a fit: Patients who have already been diagnosed with cervical cancer or those who are not eligible for HPV vaccination may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to more effective vaccination protocols against HPV, potentially reducing the incidence of cervical cancer.

How similar studies have performed: Previous research has shown promise in evaluating vaccine efficacy through serological measures, but this approach aims to establish a novel calibration standard that has not been extensively tested.

Where this research is happening

Frederick, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Cervical CancerCervix Cancer
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.